Verismo Therapeutics, the U.S. subsidiary of HLB Innovation, said interim results from a Phase 1 trial of its blood cancer CAR-T therapy SynKIR-310 demonstrated antitumor activity and a favorable safety profile.


Verismo Announces Interim Results from Phase 1 Trial of Blood Cancer Therapy... "Demonstrates Efficacy and Safety" View original image

According to Verismo on November 5, the results will be presented orally at the 2026 American Society of Hematology (ASH) meeting, which will be held in New Orleans, U.S., for four days starting December 12 (local time).


On November 4, Verismo released interim results from the Phase 1 CELESTIAL-301 trial of SynKIR-310 in the official ASH 2026 abstract. The abstract included treatment response and safety data from dose cohorts 1 and 2. At the meeting, the company will also present updated clinical results expanded through dose cohort 3, along with pharmacokinetic and pharmacodynamic (PK/PD) analysis data.


Among the five patients in the first two dose cohorts whose treatment responses could be evaluated, four responded to treatment, for an objective response rate (ORR) of 80%. Of these, three showed a complete response (CR), with no signs of cancer detected in tests, resulting in a complete response rate of 60%. The median duration of response among patients who achieved a complete response has not yet been reached, and one patient remained in complete response at the 12-month assessment after treatment.


In the blood cancer trial data, none of the six patients treated in the first two dose cohorts experienced cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), regardless of severity. No dose-limiting toxicities (DLTs) were observed either.



Brian Kim, CEO and co-founder of Verismo Therapeutics, said, "Based on the early antitumor activity and safety results observed in this trial, we will continue to evaluate the clinical potential of the KIR-CAR platform in blood cancers and solid tumors."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing